Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2023

Safety of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis as used in Clinical Practice: Results from the ARTIS Programme

Ann Rheum Dis. 2023;82(5):601–610 doi: 10.1136/ard-2022-223762

Frisell T,

Bower H,

Morin M,

Askling J; ARTIS Study group.

Nationwide register-based cohort study corroborates and extends previous evidence that the currently available biologic/targeted synthetic DMARDs have an acceptable and, on the whole, similar safety profile.

Keywords:

October 2022

Thromboembolie veineuse avec les inhibiteurs de JAK et d'autres médicaments immunomodulateurs : une étude comparative suédoise de sécurité chez des patients atteints de polyarthrite rhumatoïde

Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-223050

Bower H,

Nationwide register-based study in Sweden finds that patients with RA treated with JAKinibs in routine clinical practice are at increased risk of venous thromboembolism (VTE), compared with those treated with bDMARDs, an increase numerically confined to pulmonary embolism.